Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147435 | 0.87 | HRH3 (0.60) | ACHEHRH3SIGMAR1 | |
| SCHEMBL28037481 | 0.83 | ALDH1A1 (0.58) | ACHEHRH3 | |
| SCHEMBL6643053 | 0.80 | L3MBTL1 (0.58) | OPRD1SIGMAR1 | |
| SCHEMBL16565555 | 0.77 | ALDH1A1 (0.50) | ACHEHRH3 | |
| SCHEMBL11210779 | 0.76 | KMT2A (0.56) | ACHECDK4CCND1 | |
| SCHEMBL24569592 | 0.76 | MEN1 (0.49) | ACHE | |
| SCHEMBL2362568 | 0.75 | ALDH1A1 (0.56) | ACHEHRH3SIGMAR1 | |
| SCHEMBL16565552 | 0.75 | KDM4E (0.51) | ACHEHRH3 | |
| SCHEMBL12015834 | 0.75 | SIGMAR1 (0.43) | ACHESIGMAR1 | |
| SCHEMBL250597 | 0.74 | ACHE (0.63) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492340-B2 | Heteroaromatic electrophiles and methods of using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220204472-A1 | HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492340-B2 | Heteroaromatic electrophiles and methods of using thereof | ACHE, BCHE, CHAT | OPRD1 2024/4885ACHE 1/4885HRH3 470/4885 |
| US-20220204472-A1 | HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF | ACHE, BCHE, CHAT | OPRD1 2024/4885ACHE 1/4885HRH3 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.